ReviewFrontiers in cellular and infection microbiology2025
Reporter-expressing viruses for antiviral drug discovery research.
Review in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- NS-segment-based reporter influenza A viruses: engineering strategy, applications, and limitations.Journal of virology · 2026Review
- A Novel Cell-Based High-Throughput Screening Model for Inhibitors Targeting Influenza Virus Hemagglutinin-α-2,6-Sialic Acid Interaction.Biomolecules · 2026Article
- Advances in Detection Methods for Human Respiratory Syncytial Virus Neutralizing Antibodies.Vaccines · 2026Review
- Antiviral Activity of Essential Oil fromMolecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Viruses continue to pose major global health challenges, with recent pandemics underscoring the urgent need for effective antiviral therapeutics. While vaccines have reduced the burden of some viral diseases, many remain difficult to control. Antiviral drug discovery relies on identifying and validating suitable targets through both target-based and phenotype-based screening strategies. Traditional antiviral assays are accurate but labor-intensive and not easily adaptable for high-throughput analysis. Advances in reverse genetics have enabled the development of reporter-expressing recombinant viruses, which allow real-time tracking of viral replication and are increasingly used in high-throughput screening. This review highlights the application of fluorescent and bioluminescent reporter systems in antiviral drug discovery, emphasizing their advantages, limitations, and future prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.